OMCL Omnicell, Inc.
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.…
Industry Peers
Health Information ServicesKey Statistics
About Omnicell (NASDAQ: OMCL)
›
Omnicell (NASDAQ: OMCL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Health Information Services industry, part of the Healthcare sector, and reports about 3,450 employees.
The shares were at 33.18 USD on 19 November 2026, down 7.2% over 52 weeks. Its 52-week range is 31.75 USD to 55.00 USD: the price is 39.7% below the high and 4.5% above the low.
At a market capitalisation of 1.53B USD, it trades at 34.6 times trailing earnings and 16.5 times forward earnings. The median trailing P/E of its 14 largest Health Information Services peers is 42.1, a discount of 18% for OMCL.
Omnicell reports return on equity of 0.2%, an operating margin of 4.6% and revenue down 0.9% year over year.
It holds more cash than debt, a net cash position of 114.11M USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 7 analysts cover the stock; their mean price target of 57.43 USD is 73.1% above the current price. The next earnings report is expected on 4 February 2027.